Benchmarking the ability of novel compounds to inhibit SARS-CoV-2 main protease using steered molecular dynamics simulations

BACKGROUND: The SARS-CoV-2 main protease (M(pro)) is an attractive target in the COVID-19 drug development process. It catalyzes the polyprotein's translation from viral RNA and specifies a particular cleavage site. Due to the absence of identical cleavage specificity in human cell proteases, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Rahul, Bhardwaj, Vijay Kumar, Das, Pralay, Bhattacherjee, Dhananjay, Zyryanov, Grigory V., Purohit, Rituraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052739/
https://www.ncbi.nlm.nih.gov/pubmed/35551011
http://dx.doi.org/10.1016/j.compbiomed.2022.105572

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052739/
https://www.ncbi.nlm.nih.gov/pubmed/35551011
http://dx.doi.org/10.1016/j.compbiomed.2022.105572

Ejemplares similares